Thursday, September 30, 2021

Dawson James Securities’ 6th Annual Small Cap Growth Conference To Unify Investors and Small-cap Companies on a Common Networking Space

 Thursday- October 21, 2021

Venue- Wyndham Grand Hotel, Jupiter, FL

The Dawson James Securities’ 6th Annual Small Cap Growth Conference is being held on October 21st 2021 at the scenic Wyndham Grand Hotel, Jupiter, Florida. Small-cap industries, company executives, and investors from the healthcare, technology and consumer sectors are invited to attend this Small Cap Growth Conference. There is no fee for attendees.

Since 2004, Dawson James Securities, an investment banking firm with offices in New York, Florida and Maryland has propelled small and microcap public and private growth companies towards growth and lucrative investment opportunities.

This 6th annual Small-cap growth conference is focused on providing a unified platform for senior leadership from approximately 40 small-cap growth companies and 12 leading industry sponsors to communicate and develop productive business relationships with institutional funds, family offices and high net-worth investors.   

The event will feature keynotes and discussions from industry leaders and accredited investors about the trends and the future of investment and growth in the small-cap industries of the healthcare, consumer, and technology segment. 40 participating companies will be  showcased on the 21st with a 2-track presentation format about the nature and prospect of their business and potential benefits of association.

Dawson James Securities organizes these conferences for the benefit of small and microcap industries. The format allows potential investors to hear the presenting companies’ stories first hand and to interact directly with senior leadership teams.  This conference specifically targets small and microcap industries that seek exposure and better investment opportunities. Entrepreneurs, startups, and small industries can leverage this conference platform to reach out to investment firms and get discovered by distinguished sponsors to develop long-term networking and business alliances. 

The event will commence with registration and breakfast promptly at 8:00 a.m. on Thursday, Oct. 21, 2021, followed by corporate presentations, discussions from industry leaders, and one-on-one management meetings. 

To know more about the event https://nnw.fm/gYhQw

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Versatile DehydraTECH(TM) Technology Improving Taste, Bioabsorption, Efficacy of Drugs

 

  • Lexaria Bioscience is the global innovator behind the disruptive DehydraTECH(TM) drug delivery technology
  • DehydraTECH’s taste-masking capabilities eliminate the need for unwanted sweeteners or chemical masking agents
  • The technology also significantly increases the bioavailability of drugs, speeds up the rate of drug onset, and boosts brain absorption
  • DehydraTECH presents numerous opportunities and has been evaluated in R&D programs featuring DehydraTECH-processed nicotine, antivirals, and cannabidiol 

Oral delivery is the easiest and most convenient way to administer medications, yet it is prevalently associated with patient noncompliance owing to many drugs’ bitter taste. The problem appears widespread and necessitating remedial bitterness-masking interventions. But as recently as 2013 (relative to the mid-19th century origin of the modern pharmaceutical industry), the taste-masking of oral solid dosage forms was still a major challenge that needed to be addressed by formulation or pharmaceutical scientists (https://nnw.fm/peXsi).

The most commonly used taste-masking methods at that time were film coating and the use of sweeteners, sugars, or flavors, but the latter is considered ineffective due to its inability to adequately mask the bitter taste. Still, less conventional methods such as microencapsulation, spray drying, supercritical fluids, and more had already been reported as successful taste-masking techniques. 

Since then, Lexaria Bioscience (NASDAQ: LEXX), a global innovator whose patented DehydraTECH(TM) drug delivery technology could potentially improve oral administration of Active Pharmaceutical Ingredients (“APIs”), has led the pharmaceutical industry in advancing novel taste-masking techniques.

With part of its R&D having progressed from animal studies to human clinical studies, the company has so far established that DehydraTECH masks unwanted taste, thereby eliminating the need for sugar-filled edibles; improves the speed of drug onset; increases the effectiveness of drug delivery into the bloodstream (bioavailability); and boosts brain absorption (https://nnw.fm/wX6Ak). 

DehydraTECH’s taste-masking capabilities result from the use of fatty acids. The technology combines the API with fatty acids, such as long-chain fatty acid (“LCFA”), before applying the resultant compound to food/carrier particles (substrate material), performing dehydration synthesis procedure, and, finally, rendering it as powder or liquid for use in desired final form factor. Importantly, according to an evaluation LEXX conducted in collaboration with National Research Council, the largest R&D organization in Canada, DehydraTECH does not alter the chemical structure of the API.

The fatty acids offer dual benefits. First, they are believed to block and divert bound APIs away from bitter taste receptors, essentially rendering them flavorless, as well as odorless. “DehydraTECH formulations do not require unwanted sweeteners or chemical masking agents for flavor and odor blocking, allowing manufacturers to create low-sugar products with fewer calories, while also avoiding the use of excessive artificial sweeteners,” reads the company’s website (https://nnw.fm/It4MG).

The LCFA also promotes quick absorption into lymphatics, bypassing the first-pass liver effect, which drastically reduces the bioavailability or overall effectiveness of orally ingested drugs. In this regard and based on findings of clinical testing, DehydraTECH significantly increases bioavailability for fat-soluble drugs.

DehydraTECH has so far been evaluated as part of nicotine, antivirals, and cannabinoids (“CBD”) R&D programs. The nicotine program showed that the drug delivery platform significantly increased the quantity of nicotine delivered. It was also responsible for 295% higher brain levels of nicotine compared to controls. 

Additionally, its first 2021 human clinical study under the CBD program, HYPER-H21-1, has evidenced a rapid and sustained decline in blood pressure, with the reduction being more pronounced in the first 10 to 50 minutes of the study. The second 2021 human clinical study, HYPER-H21-2, has demonstrated up to 23% drop in blood pressure with DehydraTECH-CBD compared with placebo. Though Lexaria still awaits additional analyses, its drug delivery technology has proven useful for potentially treating hypertension.

Thirdly, its antiviral program, featuring cell-based and animal studies using Remdesivir and antiviral drugs being investigated for SARS-CoV-2 and HIV/AIDS, has demonstrated enhanced drug delivery.

Since it began developing DehydraTECH in 2014, Lexaria has significantly strengthened and broadened the technology to an unprecedented degree. Even so, more may still be in the offing for the company currently disrupting the pharmaceutical industry.

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Achieves Most Important Milestone Yet with Submission of IND Application for Phase 2a Clinical Trial

 

  • Tryp Therapeutics on September 22 submitted an IND application to the FDA to evaluate its oral formulation of synthetic psilocybin, TRP-8802, in a Phase 2a clinical study
  • The study seeks to evaluate TRP-8802 for the treatment of patients with eating disorders and will enroll 10 patients 
  • According to Tryp Chairman and CEO, the submission is the first of several IND filings the company intends to make in the coming months
  • Tryp is also preparing for Phase 2b clinical trials, which will evaluate its proprietary drug candidate, TRP-8803

During a recent investor presentation, Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing novel bioscience solutions for conditions with high unmet need, expressed its expectation to initiate at least two Phase 2a clinical trials in Q4 2021 (https://nnw.fm/UXQpX). The trials, to be conducted at the University of Florida under the guidance of Dr. Jennifer Miller, a pediatric eating disorders expert and the trials’ principal investigator, will evaluate TRP-8802, Tryp’s oral formulation of synthetic psilocybin, in combination with psychotherapy. 

The company announced September 22 that it had submitted to the US Food and Drug Administration (“FDA”) an Investigational New Drug (“IND”) application to evaluate TRP-8802 in the Phase 2a study for the treatment of patients with eating disorders (https://nnw.fm/L0Xzt), acting as its first major clinical development milestone.

According to Dr. Miller, the submission represents hundreds of hours of preparation, design, and coordination as Tryp and its partners “pursue a leading-edge treatment of psilocybin with psychotherapy.” Part of the efforts Dr. Miller was alluding to include collaborations with Clinlogix, a contract research organization (“CRO”), the University of Florida, and Fluence, a psychedelic therapy educational platform. 

In late August, Fluence undertook and completed the training of psychotherapists who will take part in the trial by overseeing dosing sessions (https://nnw.fm/Nz7sw). On its part, Clinlogix will support the upcoming Phase 2a clinical trials by providing medical writing, biostatistical analysis, data management, and trial monitoring (https://nnw.fm/lp6Bb).

The submission sets the stage for the Phase 2a clinical trial subject to a favorable review by the FDA. The study is expected to enroll 10 patients with various overeating disorders, such as hypothalamic obesity, binge eating disorder, and Prader-Willi Syndrome. The administration of TRP-8802 is expected to enhance neuroplasticity and help create healthy neural patterns associated with hunger and eating. Prior to the administration, the patients will meet with the trained psychotherapists for two sessions. The psilocybin will then be administered during two drug-dosing sessions, after which integration sessions will follow.

“This IND submission marks the most important milestone the company has achieved to date and will be critical in identifying patient responses to the active ingredient, consistent with that of our proprietary drug candidate, TRP-8803, that will be used in Phase 2b trials and beyond,” said Tryp Chairman and CEO Greg McKee. 

McKee also noted that the submission is the first of several IND filings the company expects to make in the coming months, further reiterating that Tryp is eager to begin enrolling its first patients in multiple Phase 2a trials later this year.

For Tryp, this is only the beginning. The company intends to use TRP-8803, its proprietary psilocybin-based drug product manufactured exclusively for Tryp, for Phase 2b clinical trials, and beyond. It has already announced partnerships with the University of Michigan, Calvert Labs, and Gad Consulting to conduct bridging studies in preparation for Phase 2b clinical trials, with more collaborations possibly still in the works. In this regard, the clock has begun counting what will likely be hundreds of additional hours of preparation, design, and coordination in readiness for the Phase 2b trials.

For more information, visit the company’s website at www.TrypTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://nnw.fm/TRYPF

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Communications Tech and Data Services Provider FingerMotion Inc. (FNGR) Building Strong IP in China’s Large Insurance Market

 

  • FingerMotion Inc., has become a provider for China’s booming e-commerce market with rich communication services (“RCS”) and big-data insights, developing its Sapientus database as a solution for clients’ predictive services needs
  • In addition to its SMS, MMS and mobile top-up business, FingerMotion’s focus on adapting Sapientus to the needs of the insurance industry are driving revenues to new records each quarter
  • In China, insurance is compulsory to protect certain societal needs, such as pensions, medical care, employment (and unemployment), and maternity care, creating a ready market for insurance providers
  • The Sapientus platform creates proprietary matrices for assessing consumer risk potential using context-based outlooks in accordance with established behaviors

The development of business capabilities to harvest and apply big data insights is affecting revenue streams that vary in size and impact from national government contractors (https://nnw.fm/t6e5k) to farmers harvesting their fields (https://nnw.fm/2sP6j). 

Industry e-magazine Datamation reported Sept. 26 on Splunk findings that “organizations with ‘mature data practices’ release twice as many products and increase employee productivity at double the rate of organizations with less mature data practices” (https://nnw.fm/nQroA).

Big data communications technology innovator FingerMotion (OTCQX: FNGR) is focusing its new platform on China’s insurance market as the nation serving as the home to some 1.4 billion people continues to build a powerful economy on the efforts of factories crucial to the global supply chain. 

FingerMotion launched its Big Data Insights division with its flagship database IP Sapientus last year and attracted global insurance behemoth Pacific Life Re-insurance as a client interested in developing a customer base within China. 

Sapientus is a stand-out technology that applies publicly available data to clients’ risk forecast needs, generating proprietary matrices that assimilate information on individuals’ behaviors to create context-based outlooks for customers. 

It’s a service that’s particularly attractive in China since the country’s credit and insurance risk standards are still in a developmental stage and Sapientus can help provide an alternative means of judging potential liabilities for a corporate client. 

During the past year, FingerMotion’s revenues have seen steady growth, largely due to mobile communications services, and the Pacific Life agreement earlier this year positioned it for an even more promising future.  CEO Martin Shen said during a corporate update conference call discussing the company’s first-quarter financial results in August that FingerMotion’s top-up business had risen 341 percent and mobile SMS and MMS services had increased by 77 percent, and that “some significant funds” raised after the quarter ended will likely lead to a higher outcome on the balance sheet once the Q2 report is completed. 

“Most of the e-commerce companies operate in the red for quite a while before they turn a profit, but our current trajectory has us moving in that profitable direction a bit quicker than maybe other companies have been,” Shen said (https://nnw.fm/3u53X). 

Shen acknowledged that the company has considered eventually focusing its big data platform on other industries beyond insurance and in markets beyond China’s borders, but said the company needs to stay focused on its immediate purpose before expanding its reach. 

“We’ve always thought of the ability of the algorithms that we have. It’s not really just to perfect those algorithms but it’s also to have them exportable and replicated in other jurisdictions, in other markets. … But again, that takes time to develop, and we’re really still developing what we’re doing right now in China,” Shen said. “Right now, let’s just build and make sure that our foundation is strong first.”

For more information, visit the company’s website at www.FingerMotion.com.

NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://nnw.fm/FNGR

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Friendable Inc. (FDBL) Changing How Musical Artists Earn Revenue in an Industry That Is Constantly Changing

 

  • Some social media platforms, like TikTok, pay artists for their music, but the amounts are insignificant, and an artist’s musical track would have to be used hundreds of thousands of times to make a decent profit
  • Friendable’s Fan Pass Live provides artists an online platform to share their music content and earn a profit
  • Artists earn on Fan Pass through fan subscriptions, merchandise sales, ticket sales, and more
  • Fan Pass artists have access to Pro Services that include logo design and merchandise, as well as social media promotions for upcoming events

2020 was a year of change (and growth) for the music industry. Streaming replaced in-person shows, and artists were forced to adapt and evolve to stake a piece of the revenue. Fast-forwarding to today, live streaming shows and other events are the new normal. More and more artists are entering the virtual stage without representation, simply going online to do what they love and earn money in the process.

Artists don’t have to rely solely on social media platforms like TikTok, with revenue structures that constantly change, to gain recognition for their craft. For example, TikTok does pay its artists revenue, but it is based on the number of times their song is used to make a video. Each time the track is used to create a video, it is considered a “creation,” the metric value in which TikTok measures popularity for revenue purposes. To make a living off of TikTok alone, artists would need to secure hundreds of thousands of creations each month (https://nnw.fm/w6SHQ). 

A more attractive and lucrative revenue-generating option available for up-and-coming artists is the Fan Pass platform, launched in July 2020 by Friendable (OTC: FDBL). On the Fan Pass streaming artist platform, artists can build up a fan base, gain access to merchandising, and earn revenue while doing what they love. Each artist has the opportunity to earn revenue from the monthly subscription fee that fans pay to gain access to the Fan Pass artist catalog, merchandise purchases, and even 100% of ticket sales for exclusive live-streamed content and videos on-demand.

Artists also have access to premium equipment available for purchase and exclusive Artist Pro Services. The Artist Pro Services are offered in three tiers – basic, standard, and a premium-style option. Each is priced accordingly and offers artists options for logo design, merchandise designs, and marketing material. The process is easy to get started. Artists fill out a form answering survey questions, the prototype is created, and artists then communicate what they like, don’t like, or want to be changed. Packages are even available for social media promotion of upcoming events. Prices range from $45 for a social ad/announcement design to promote the next three events to a $400 pro merch collection with five high-resolution designs placed in the store on any five merchandise items available.

Friendable is currently implementing a 120-day plan that strategizes growth for the Fan Pass platform. The company has already accomplished creating and releasing version 2.0 of the platform, gaining acceptance from the Apple Store and Google Play Store for the new application, and launching a brand awareness campaign, among others. Additionally, Fan Pass has begun promoting Pro Services to help artists receive revenue for doing what they love.

With this approach and the wealth of services and benefits available, Fan Pass is in a unique position to disrupt the music streaming market, an expanding sector that is growing in value from $20.6 billion in 2019 to an anticipated $60.5 billion by 2026 (marking a CAGR of 16%). The immediate increase for this market segment is due to the increased availability of the internet and access to online content through services like Fan Pass (https://nnw.fm/IDxVm). 

For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com

NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at https://nnw.fm/FDBL

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Latin America All-In on Supporting the Future of Cannabis

 NetworkNewsWire Editorial Coverage: While North America is the leading cannabis market, the federal government appears reluctant to legalize the substance and remove major legislative roadblocks to the market’s continued growth and success. Countries in South America, however, seem much more eager to embrace the future of cannabis, with several countries passing new laws designed to end cannabis prohibition and support the growing industry. This government support will likely generate government revenue, cut into illicit sales and provide innovative treatment options to people in need. Colombia, Mexico and Panama have established themselves as leaders in the global move toward cannabis progress, which is good news for Flora Growth Corp. (NASDAQ: FLGC) (Profile), which has a cultivation facility in Colombia. Other major players in the cannabis sector, including Aurora Cannabis Inc. (NASDAQ: ACB), Cronos Group Inc. (NASDAQ: CRON), HEXO Corp. (NASDAQ: HEXO) and GrowGeneration Corp. (NASDAQ: GRWG), are paying close attention to what’s taking place on the worldwide cannabis stage as each major move is likely to have global ramifications.

  • LATAM countries are making moves designed to provide stronger support for legal cannabis industries.
  • An emerging leader in Colombia, Flora Growth has built an impressive portfolio of brands along with dozens of licenses and burgeoning distribution networks globally.
  • Flora’s Colombian 247-acre cultivation operations produce premium organic cannabis at $0.06 per gram, almost 98% cheaper than some Canadian peers.
  • A family of companies and massive land position may give Flora Growth a competitive edge in the wake of newly passed Colombian legislation.

Catching Investment Attention

As South American countries, known as LATAM, show support for the future of cannabis, the region has caught the attention of the investment world. That support is exemplified in a variety of ways, including Mexico’s Supreme Court opening the door to adult-use marijuana legalization by declaring prohibition of recreation cannabis as unconstitutional. In addition, Panama legalized medical marijuana, bringing the country in line with at least seven other LATAM countries that allow some form of cannabis at the federal level.

And in what might be the biggest LATAM cannabis news of the summer, Colombia authorized exports of dried cannabis flower for medical use, that last in a series of legislative changes supporting legal cannabis. Previously the country had established cannabis infrastructure by allowing production, distribution and exports of cannabis goods such as seeds and derivatives. However, had stopped short of legalizing the export of dried flower — the most popular version of the plant. That all changed when the government issued Decree 811, making the country’s intentions clear to be a market leader.

As the operator of one of the largest outdoor, organic cannabis cultivation facilities in Colombia, Flora Growth Corp. (NASDAQ: FLGC) benefits from production costs that are significantly below industry averages. In addition to lower production costs, Flora Growth also has the distinction of being the first traditional cannabis company to IPO on the Nasdaq exchange and successfully completed its initial public offering in May.

Flora’s cannabis involvement in Colombia reaches beyond cultivation. The company has diversified businesses the include production, research and development, wholesale, and consumer packaged goods that features a brand portfolio including pharmaceuticals, textiles, cosmetics, and food and beverage goods. In fact, Flora offerings include more than 340 products, 70-plus medical and cosmetic licenses and more than 2,500 points of distribution across LATAM and the United States with sales across 13 other countries. The company lists an impressive roster of Colombian partners as well, including Importaciones y Asesorias Tropi S.A.S., better known as Tropi, the largest food distributor in Colombia.

Just as the new Colombian export laws go into effect, Flora’s sales channels are expanding internationally, with distribution reaching throughout LATAM and beyond into Europe and the United Kingdom. In June, Flora announced plans to acquire Switzerland-based Koch & Gsell, the parent of the hemp cigarette brand Heimat, a move that portends future revenue increase as well. The company also signed a letter of intent for a 2-million-euro investment in the European cannabis company Hoshi International Inc.

Ultra-Low Labor & Production Costs

The second edition of the Latin America and Caribbean Cannabis Report, released by Prohibition Partners, reports that low-cost labor and construction costs in the LATAM region could result in regional cannabis production costs up to 80% lower than North American counterparts. Leveraging this advantage, Flora has reported production costs in pilot programs on the company’s 10.8 million square feet (247 square acres) of licensed land at only $0.06 per gram of cannabis, about 97% less than the reported costs of Aphria and Sundial (~$1.85/gram).

Flora achieves these ultra-low production expenses by combining low labor costs, zero-cost water from the property’s six natural springs and high yields from near-ideal climate conditions that lead to at least three harvests annually. It’s worth nothing that low-cost labor doesn’t mean  unskilled labor. The Colombian economy revolves around agriculture, including growing cut flowers that supply more than 70% of all those imported by the United States.

The Power of Partnerships

In another key advantage, Flora has developed powerful partnerships, its most recent being  a new joint venture with Canada’s Avaria, the owner of the popular KaLaya brand pain cream sold across Canada at leading retailers including Loblaws, Walmart and London Drugs. The partnership is ideal because Avaria does not hold a Canadian license to produce cannabis-derived versions of its products at a commercial scale. Therefore, according to the agreement, Avaria will supply the product and Flora will distribute it throughout its extensive LATAM network; plans are also underway to expand into U.S. markets. In addition, FLGC’s Colombian Flora Lab intends to produce KaLaya’s CBD-infused products using cannabinoids from Flora’s Colombian cultivation facility, Cosechemos.

Another partnership was forged this summer when Flora’s Kasa Wholefoods Co. signed a sales agreement with Tropi to begin placing Kasa products throughout the country. The first shipment, valued at $1.1 million, was delivered in July, the initial order on the one-year contract. Flora management anticipates that contract will increase to $2 million monthly over time for its food and beverage portfolio.

Mambe, Kasa’s leading brand, has almost 1,000 distribution points throughout Colombia, including Tostao’ Café & Pan, one of Colombia’s largest coffee chains. The company plans to expand to more than 1,200 locations by year’s end. Mambe also counts the award-winning Latin-American actress Laura Londoño as its brand ambassador. And Londoño isn’t the only widely recognized Flora advocate. Former Miss Universe (2014) and Miss Colombia (2013) Paulina Vega is a founding partner in Flora Beauty products.

Ramping Up Allowed

Flower export laws aren’t the only legislative signs of Colombia’s commitment to support cannabis. Other new laws provide for the manufacturing, sale and export of cannabinoid ingestible products; substantially reduce marketing restrictions on domestic cannabis products, which means brands can advertise their products; allow for the sale of cannabinoid medical products as “custom formulas” available at drugstores, meaning pharmacists can prescribe and prepare products designed to complement medical prescriptions specific to a patient; and allow full industrial use of cannabis in textiles, plastics, paper and construction materials.

These important changes impact Flora because of their scalability of operations. The company has run pilot tests on about five acres, leaving more than 240 acres available as the company starts ramping up operations. In addition, Flora has rights to license another 5,268 acres (230.3 million square feet) in in north-central Colombia.

An Enviable Position

While progress in the cannabis space may seem slow at times, global adaptation and acceptance appear certain. The real question is when not if, and as support spreads, companies already operating in the space will be in an enviable position as they benefit from the true potential of the market.

Aurora Cannabis Inc. (NASDAQ: ACB) launched three new proprietary cultivars under the company’s premium adult-use cannabis brand San Rafael ’71; the three new offerings are Stonefruit Sunset, Lemon Rocket and Driftwood Diesel. Guided by consumer insights to identify highly desirable traits, the new cultivars were developed at Aurora Coast, ACB’s state-of-the-art research facility dedicated to cannabis breeding, which is also home to one of the largest and most comprehensive genetic libraries in the world. The new hybrid and indica cultivars are also the first adult-use flower products Aurora has commercialized from Aurora Coast.

Cronos Group Inc. (NASDAQ: CRON) has partnered with Ginkgo Bioworks to produce cultured cannabinoids. The two companies recently announced the achievement of the first target productivity milestone in that collaboration. Using Ginkgo’s platform for organism design and development, Cronos Group has successfully achieved the productivity target for cannabigerolic acid (“CBGA”), which will support the Cronos Group’s planned CBG product launch this fall. “As leading companies in our respective industries, Cronos Group and Ginkgo are uniquely positioned to elevate the cannabis industry through cannabinoid and product innovation to unlock the next generation of its potential,” said Cronos group president and CEO Kurt Schmidt.

HEXO Corp. (NASDAQ: HEXO) announced the completion of its previously announced acquisition of Redecan, Canada’s largest privately owned licensed cannabis producer. The transaction included HEXO obtaining all of the outstanding shares of the entities that carry on the Redecan business. “This is an exciting day for HEXO and Redecan employees, investors, consumers and stakeholders,” said HEXO CEO and co-founder Sebastien St-Louis. “The completion of this transaction is aligned with our corporate growth strategy and will further strengthen our position as a leader in the Canadian cannabis industry, bolstering the combined company as we look towards becoming a top-three global cannabis products company and continue on the path towards positive EPS.”

GrowGeneration Corp. (NASDAQ: GRWG) has opened two new hydroponic garden centers to serve the largest hydroponic market in the country: Los Angeles County, California. The two new super garden centers, which are the 11th and 12th locations for the company, give GrowGen an additional 122,000 square feet of retail and distribution space. The two stores, the largest hydroponic garden centers in Southern California, position GrowGen to sell to the highest concentration of commercial indoor cannabis growers in California. GrowGen is defining the next generation of garden centers, with the largest selection, best service and grow professionals, to deliver solutions for all types of growers.

Growing government support around the world bodes well for the cannabis industry, and companies operating in countries making significant moves in that direction should see significant advantages.

For more information about Flora Growth Corp. (NASDAQ: FLGC), please visit Flora Growth Corp. (NASDAQ: FLGC).

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a financial news and content distribution company, one of 50+ brands within the InvestorBrandNetwork (“IBN”), that provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.